Is Mesoblast Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Mesoblast Ltd (MSB.AX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Mesoblast Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Mesoblast Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Mesoblast Ltd?

Muslim investors may consider investing in Mesoblast Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Mesoblast Ltd classified as NOT HALAL?

Musaffa determines the Shariah status of Mesoblast Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Mesoblast Ltd updated?

The Shariah compliance status of Mesoblast Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Mesoblast Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Mesoblast Ltd?

You can check the latest Shariah compliance status of Mesoblast Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

MSB.AX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 25, 2026

Report Source: 2026 2nd Quarter Report

Mesoblast Ltd. Stock Analysis MSB.AX

Australia Health Care Mid Cap Report: Q2, 2026

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Key Statistics of Mesoblast Ltd (MSB.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD2.07AUD2.13

Today's Open

AUD2.07

Volume

2.49M

P/E Ratio (TTM)

52 Week Range

AUD1.53AUD3.31

Market Cap

2.85B

Avg. Volume

877.75K

Dividend Yield

Financial Metrics & Statements of Mesoblast Ltd (MSB.AX)

FAQ's for Mesoblast Ltd (MSB.AX)

According to Musaffa’s Shariah screening methodology, Mesoblast Ltd (MSB.AX) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.